Drug touted by Trump as COVID-19 treatment tied to increased risk of death - study
By Michael Erman and Ankur Banerjee (Reuters) - The malaria drug hydroxychloroquine, which U.S. President Donald Trump says he has been taking and has urged others to use, was tied to increased risk of death in hospitalized COVID-19 patients, according to a large study published in the medical journal Lancet. In the study https://www.thelancet.com/lancet/article/s0140673620311806 that looked at over 96,000 people hospitalized with COVID-19, those treated with hydroxychloroquine or the related chloroquine had higher risk of death than patients who were not given the medicines.
By Michael Erman and Ankur Banerjee
(Reuters) - The malaria drug hydroxychloroquine, which U.S. President Donald Trump says he has been taking and has urged others to use, was tied to increased risk of death in hospitalized COVID-19 patients, according to a large study published in the medical journal Lancet.
In the study https://www.thelancet.com/lancet/article/s0140673620311806 that looked at over 96,000 people hospitalized with COVID-19, those treated with hydroxychloroquine or the related chloroquine had higher risk of death than patients who were not given the medicines.
The authors said they could not confirm whether taking the drug resulted in any benefit in coronavirus patients.
"Urgent confirmation from randomized clinical trials is needed," they wrote. This study was not a placebo-controlled trial.
Hospitalized patients tend to have a more severe version of COVID-19. Some proponents of the drugs as treatments for the disease argue that they may need to be administered at an earlier stage in order to be effective.
There are ongoing randomized, controlled clinical trials to study the drug's effectiveness in preventing infection by the new coronavirus as well as treating mild to moderate COVID-19. Some of those trials may yield results within weeks.
Demand for decades-old hydroxychloroquine has surged as Trump repeatedly pushed for its use against the coronavirus, urging people to try it. "What have you got to lose," he said.
This week, Trump said he has been taking hydroxychloroquine as a preventative medicine, despite a lack of scientific evidence.
The Lancet study authors suggested the medicines should not be used to treat COVID-19 outside of clinical trials until those studies confirm their safety and efficacy for COVID-19 patients.
The U.S. Food and Drug Administration has said hydroxychloroquine should only be used for hospitalized COVID-19 patients or those in clinical trials. The drug has been tied to dangerous heart rhythm problems.
The Lancet study looked at data from 671 hospitals, where 14,888 patients were given either hydroxychloroquine or chloroquine, with or without an antibiotic, and 81,144 patients who were not treated with those drugs.
Both hydroxychloroquine and chloroquine have shown evidence of being effective against the coronavirus in a lab setting, but studies of the drugs in patients have proven inconclusive at best.
Several small studies in Europe and China spurred interest in using hydroxychloroquine against COVID-19, but were criticized for lacking scientific rigor.
Several more recent studies have not shown the drug to be an effective treatment for the disease. Last week, two studies published in the medical journal BMJ showed that patients given hydroxychloroquine did not improve significantly over those who were not.
In addition to malaria, hydroxychloroquine is used to treat lupus and rheumatoid arthritis.
(Reporting by Ankur Banerjee and Manas Mishra in Bengaluru and Michael Erman in New York; Editing by Saumyadeb Chakrabarty, Bill Berkrot and Jonathan Oatis)
This story has not been edited by Firstpost staff and is generated by auto-feed.
By Robin Emmott and John Irish | BRUSSELS/PARIS BRUSSELS/PARIS France and Germany will agree to a U.S. plan for NATO to take a bigger role in the fight against Islamic militants at a meeting with President Donald Trump on Thursday, but insist the move is purely symbolic, four senior European diplomats said.The decision to allow the North Atlantic Treaty Organization to join the coalition against Islamic State in Syria and Iraq follows weeks of pressure on the two allies, who are wary of NATO confronting Russia in Syria and of alienating Arab countries who see NATO as pushing a pro-Western agenda."NATO as an institution will join the coalition," said one senior diplomat involved in the discussions. "The question is whether this just a symbolic gesture to the United States
BEIJING Chinese President Xi Jinping on Wednesday called for greater efforts to make the country's navy a world class one, strong in operations on, below and above the surface, as it steps up its ability to project power far from its shores.China's navy has taken an increasingly prominent role in recent months, with a rising star admiral taking command, its first aircraft carrier sailing around self-ruled Taiwan and a new aircraft carrier launched last month.With President Donald Trump promising a US shipbuilding spree and unnerving Beijing with his unpredictable approach on hot button issues including Taiwan and the South and East China Seas, China is pushing to narrow the gap with the U.S. Navy.Inspecting navy headquarters, Xi said the navy should "aim for the top ranks in the world", the Defence Ministry said in a statement about his visit."Building a strong and modern navy is an important mark of a top ranking global military," the ministry paraphrased Xi as saying.